市场调查报告书
商品编码
1466639
转染试剂和设备市场:按产品、方法、应用和最终用户划分 - 全球预测 2024-2030Transfection Reagents & Equipment Market by Product (Equipment, Reagents), Method (Biochemical Methods, Physical Methods, Viral Methods), Application, End User - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年转染试剂和设备市场规模为24.8亿美元,2024年达27.9亿美元,预计2030年将达到57.6亿美元,复合年增长率为12.76%。
转染试剂和设备在分子和细胞生物学领域至关重要,有助于将核酸引入细胞。这个过程对于遗传学、蛋白质生产和治疗药物开发的研究和开发至关重要。在生技药品生产成长、合成基因需求增加以及细胞研究进步的推动下,全球转染试剂和设备市场正在扩大。生物治疗研究活动的活性化以及生物技术和製药研发投资的增加正在推动市场成长。基因治疗领域的不断扩大和新疫苗的开发正在增加转染试剂和设备的使用。转染试剂和先进设备的高成本以及取决于细胞类型的转染效率和活力的某些限制阻碍了市场成长。更有效率、细胞毒性更低的转染方法的技术进步以及能够有效转染多种细胞类型的新型、毒性更低的转染试剂的新兴市场的开拓预计将创造市场成长机会。
主要市场统计 | |
---|---|
基准年[2023] | 24.8亿美元 |
预测年份 [2024] | 27.9亿美元 |
预测年份 [2030] | 57.6亿美元 |
复合年增长率(%) | 12.76% |
扩大转染试剂的使用,以促进和增强产品遗传物质的传递
转染设备在将遗传物质引入细胞中起着至关重要的作用。此部分通常包括电穿孔器、反应器和其他物理或机械系统,旨在促进核酸有效且受控地引入细胞中。试剂是转染过程中使用的化学物质或製剂,可促进或增强遗传物质引入细胞。常见类型包括脂质载体、磷酸钙载体和病毒载体,每种载体都根据转染标靶具有不同的益处。不同的实验设定需要特定类型的设备。电穿孔系统适用于难转染细胞株和原代细胞的高效转染,反应器有利于治疗药物生产的大规模转染。另一方面,磷酸钙在高通量应用中转染贴壁细胞具有成本效益。
最终用户:製药和生物技术公司的转染试剂和设备在疫苗和基因疗法的开发中具有很大的潜力。
学术和研究机构主要致力于推进各领域的科学研究,包括遗传学、分子生物学和生物化学。对于这些研究机构来说,转染试剂和设备对于实验和研究目的至关重要,尤其是基因表现研究、克隆和蛋白质生产。此类实验室通常更喜欢经济高效、可靠且易于使用的解决方案,这些解决方案可以在不影响细胞活力的情况下实现高转染率。安全性和可重复性也是重要的考虑因素。对于製药和生物技术公司来说,转染技术对于药物发现、治疗研究以及疫苗和基因疗法开发至关重要。这些公司优先考虑高吞吐量能力、扩充性和准确性。我们专注于加快研发进程,并为成功的商业性应用取得一致且可重复的结果。临床试验中的监管合规性和扩充性是更重要的因素。
区域洞察
在美洲,生物技术和製药领域的研发受到高度重视,对转染试剂和设备的需求不断增长。这些地区的客户优先考虑品质和效率,并需要最新的高通量转染技术来加速药物发现和基因研究方法。对个人化医疗和基因治疗计划的投资也在增加,增加了对根据消费者需求量身定制的医疗保健解决方案的需求。欧盟 (EU) 国家因其在基因研究方面的监管领导力和严格的转染实验品质标准而脱颖而出。这导致学术机构和生技产业之间的合作加强,创造了促进创新转染技术发展的市场环境。在中东和非洲,人们对转染技术的兴趣日益浓厚,这主要是由于医疗保健和教育领域的投资增加。包括中国、日本和印度在内的亚太地区是一个由市场动态的市场,受到生物技术研究的巨额投资、蓬勃发展的製药业以及旨在解决当地流行疾病的基因研究的激增所驱动,这是一个充满活力的市场。中国处于领先地位,政府对生物技术的大力支持,以及基于 CRISPR 的基因组编辑工具等新型转染技术的专利数量不断增加。日本和印度透过再生医学和疫苗研究也显示出巨大的市场成长潜力。
FPNV定位矩阵
FPNV定位矩阵对于评估转染试剂和设备市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对转染试剂和设备市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4.竞争力评估与资讯:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1.转染试剂及设备市场规模及预测如何?
2.转染试剂和设备市场预测期间需要考虑投资的产品、细分市场、应用和领域有哪些?
3. 转染试剂和设备市场的技术趋势和法规结构是什么?
4.转染试剂及设备市场主要厂商的市场占有率如何?
5. 进入转染试剂和设备市场的合适型态和策略手段是什么?
[193 Pages Report] The Transfection Reagents & Equipment Market size was estimated at USD 2.48 billion in 2023 and expected to reach USD 2.79 billion in 2024, at a CAGR 12.76% to reach USD 5.76 billion by 2030.
Transfection reagents & equipment are pivotal in the field of molecular and cellular biology, facilitating the introduction of nucleic acids into cells. This process is essential for research and development in genetics, protein production, and therapeutic drug development. The global market for transfection reagents and equipment is expanding, driven by the growth in biologics production, the rising demand for synthetic genes, and advancements in cell research. Increased research activities in biotherapeutics, along with rising investments in biotechnology and pharmaceutical R&D, are driving market growth. Continuous expansion of the gene therapy sector and the development of novel vaccines are expanding the usage of transfection reagents & equipment. The high cost of transfection reagents and sophisticated equipment and certain limitations in transfection efficiency and survival rates in some cell types hampers the market growth. Technological advancements in transfection methods for higher efficiency and lower cytotoxicity and the rising development of novel, low-toxicity transfection reagents that can efficiently transfect a wide range of cell types are expected to create opportunities for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 2.48 billion |
Estimated Year [2024] | USD 2.79 billion |
Forecast Year [2030] | USD 5.76 billion |
CAGR (%) | 12.76% |
Product: Growing usage of transfection reagents to facilitate or enhance the delivery of genetic materials
Transfection equipment plays a pivotal role in delivering genetic material into cells. This segment typically includes electroporators, bioreactors, and other physical or mechanical systems designed to facilitate the efficient and controlled introduction of nucleic acids into cells. Reagents are chemicals or formulations used in transfection procedures to facilitate or enhance the delivery of genetic material into cells. Common types include lipid-based, calcium phosphate, and viral vectors, each offering distinct advantages depending on the transfection target. Different experimental setups require specific types of equipment. Electroporation systems are preferred for their high-efficiency transfection of difficult-to-transfect cell lines and primary cells, while bioreactors offer an advantage in large-scale transfections for therapeutic manufacturing. Lipid-based reagents are widely used for their versatility and ease of use across a broad range of cell types, whereas calcium phosphate is cost-effective for transfecting adherent cells in high-throughput applications.
End User: High potential of transfection reagents & equipment across pharmaceutical & biotechnology companies for the development of vaccines and gene therapies
Academic & research institutes primarily focus on the advancement of scientific research in various fields, including genetics, molecular biology, and biochemistry. For these institutions, transfection reagents and equipment are crucial for experimental and research purposes, particularly in gene expression studies, cloning, and protein production. They often prefer cost-effective, reliable, and easy-to-use solutions that can yield high-efficiency transfection rates without compromising cell viability. Safety and reproducibility are also key considerations. For pharmaceutical & biotechnology companies, transfection technologies are instrumental in drug discovery, therapeutic research, and the development of vaccines and gene therapies. These entities prioritize high-throughput capabilities, scalability, and precision. The focus is on obtaining consistent and reproducible results that can expedite the R&D process and lead to successful commercial applications. Regulatory compliance and scalability for clinical trials are additional critical factors.
Regional Insights
In the Americas, the need for transfection reagents & equipment is driven by a strong emphasis on research and development in the biotechnology and pharmaceutical sectors. Customers in these regions prioritize quality and efficiency, seeking out the latest high-throughput transfection technologies to accelerate drug discovery and genetic research processes. Investments in personalized medicine and gene therapy projects are substantial, aiming to cater to the increasing consumer need for tailored healthcare solutions. European Union (EU) countries stand out for their regulatory leadership in genetic research and strict quality standards for transfection experiments. This has fostered a market environment where collaboration between academic institutions and the biotech industry flourishes, driving forward the development of innovative transfection technologies. The Middle East & Africa show a growing interest in transfection technologies, mainly due to the increasing investment in healthcare and education sectors. The Asia-Pacific region, including China, Japan, and India, presents a dynamic and rapidly expanding market for transfection reagents & equipment market with massive investment in biotechnology research, a burgeoning pharmaceutical industry, and a surge in genetic studies aimed at addressing prevalent local diseases. China is at the forefront, with significant government backing for biotech initiatives and a growing number of patents related to novel transfection techniques, such as CRISPR-based genome editing tools. Japan and India also show substantial market growth potential, driven by research in regenerative medicine and vaccines.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Transfection Reagents & Equipment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Transfection Reagents & Equipment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Transfection Reagents & Equipment Market, highlighting leading vendors and their innovative profiles. These include Active Motif, Inc., Agilent Technologies, Inc., Altogen Biosystems, Applied Biological Materials Inc., Bex Co., Ltd., Bio-Rad Laboratories, Inc., BioVision, Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Fugent, LLC, GeneCopoeia, Inc., IBA Lifesciences GmbH, Lonza Group Ltd., MaxCyte, Inc., Merck KGaA, Mirus Bio LLC, Omega Bio-tek, Inc., OriGene Technologies Inc., PerkinElmer, Inc., Polyplus-Transfection SA by Sartorius AG, Promega Corporation, Qiagen N.V., Sartorius AG, SBS Genetech Co., Ltd., Sutter Instrument Co., Takara Bio Inc., Tecan Trading AG, Thermo Fisher Scientific Inc., and TransGen Biotech Co., Ltd..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Transfection Reagents & Equipment Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Transfection Reagents & Equipment Market?
3. What are the technology trends and regulatory frameworks in the Transfection Reagents & Equipment Market?
4. What is the market share of the leading vendors in the Transfection Reagents & Equipment Market?
5. Which modes and strategic moves are suitable for entering the Transfection Reagents & Equipment Market?